RedHill Biopharma and IntelGenx Announce First European Marketing Approval of RIZAPORT(TM) (RHB-103) for Migraines http://globenewswire.ca/news-release/2015/11/09/785064/10155663/en/RedHill-Biopharma-and-IntelGenx-Announce-First-European-Marketing-Approval-of-RIZAPORT-TM-RHB-103-for-Migraines.html#sthash.waxXktXs.dpuf